CALGARY, ALBERTA -- (MARKET WIRE) -- December 05, 2006 -- Resverlogix Corp. ("Resverlogix") (TSX: RVX), announced that the Company's lead drug candidate RVX208 unique mechanism of action (MOA) is well positioned in the emerging HDL therapeutic market segment for reducing atherosclerosis and heart disease. Given recent events in the marketplace regarding cholesterol management drugs, Resverlogix verifies that its lead candidate will be tested in humans Q1 2007. It is imperative to understand that one of the most important factors for a successful drug target is to have large bodies of clinical evidence to support it, which Resverlogix does. More than 200,000 subjects have participated in the landmark Esperion trial and other major epidemiology trials such as AMORIS and INTERHEART. These clinical studies have built a very compelling body of evidence that ApoA-I, not other targets such as CETP or PPAR, has the most robust clinical validation demonstrating a reduction in cardiovascular disease risk.
